Lupin acquires Sanofi brands Aarane and Nalcrom in Europe and Canada

New Delhi: Lupin Limited has completed its acquisition of two renowned brands, Aarane™ in Germany and Nalcrom™ in Canada and the Netherlands, from Sanofi through its European hub entity, Lupin Atlantis Holdings SA.

This deal also includes the acquisition of their trademark rights from Sanofi.

The acquisition aligns with Lupin’s ongoing strategy to expand its presence in the specialty pharmaceuticals sector. By integrating these brands, Lupin aims to enhance its respiratory business in Germany, particularly by strengthening the recently established franchise that includes the introduction of Luforbec™.

Dr. Fabrice Egros, President of Corporate Development at Lupin, stated, “This acquisition will strengthen our global position in treating patients suffering from diverse respiratory diseases and conditions, and it adds accretive assets in gastrointestinal care that broaden our portfolio of branded products. We are committed to providing our customers and patients with the best products and services in the market segments where we are present, improving the quality of life for millions of people around the world.”

Nalcrom™ (sodium cromoglicate Oral) is classified as an anti-allergic medication. It is primarily used for treating food allergies, following specific allergen sensitivity testing and concurrent allergen restriction.

Aarane™ (sodium cromoglicate/reproterol hydrochloride pressurized inhalation) is designed for the symptomatic acute treatment of sudden asthma attacks, which may be allergic in nature or triggered by exertion, stress, or infections. It is also used for the targeted prevention of exercise-induced asthma or in situations with foreseeable allergen exposure.